K. Wada-isoe, Yoshio Tsuboi, Hiroyuki Kondo, Yoshitsugu Kojima, T. Takeshima, K. Iwasaki
{"title":"日本帕金森病的非麦角多巴胺激动剂治疗：一项索赔数据库分析","authors":"K. Wada-isoe, Yoshio Tsuboi, Hiroyuki Kondo, Yoshitsugu Kojima, T. Takeshima, K. Iwasaki","doi":"10.1111/ncn3.12689","DOIUrl":null,"url":null,"abstract":"Levodopa monotherapy and combination therapy with non‐ergot dopamine agonists (DAs; pramipexole, ropinirole, and rotigotine) are commonly used in patients with Parkinson's disease (PD). Changes in prescription preferences for each DA were reported previously; however, information regarding the selection of individual DAs is insufficient.","PeriodicalId":19154,"journal":{"name":"Neurology and Clinical Neuroscience","volume":"11 1","pages":"63 - 71"},"PeriodicalIF":0.4000,"publicationDate":"2023-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Non‐ergot dopamine agonist therapy for Parkinson's disease in Japan: A claims database analysis\",\"authors\":\"K. Wada-isoe, Yoshio Tsuboi, Hiroyuki Kondo, Yoshitsugu Kojima, T. Takeshima, K. Iwasaki\",\"doi\":\"10.1111/ncn3.12689\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Levodopa monotherapy and combination therapy with non‐ergot dopamine agonists (DAs; pramipexole, ropinirole, and rotigotine) are commonly used in patients with Parkinson's disease (PD). Changes in prescription preferences for each DA were reported previously; however, information regarding the selection of individual DAs is insufficient.\",\"PeriodicalId\":19154,\"journal\":{\"name\":\"Neurology and Clinical Neuroscience\",\"volume\":\"11 1\",\"pages\":\"63 - 71\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2023-01-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurology and Clinical Neuroscience\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1111/ncn3.12689\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology and Clinical Neuroscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/ncn3.12689","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Non‐ergot dopamine agonist therapy for Parkinson's disease in Japan: A claims database analysis
Levodopa monotherapy and combination therapy with non‐ergot dopamine agonists (DAs; pramipexole, ropinirole, and rotigotine) are commonly used in patients with Parkinson's disease (PD). Changes in prescription preferences for each DA were reported previously; however, information regarding the selection of individual DAs is insufficient.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
